HeartBeam Enrolls First Patients for the Clinical Evaluation of AIMIGo System for Arrhythmia Detection
Shots:
- HeartBeam has reported the first patients recruitment for the clinical evaluation of the AIMIGo System which is based on 3D vector electrocardiography (3D VECG) technology, in the VALID-ECG trial
- The VALID-ECG study will determine the quantitative & qualitative performance of 12-lead ECG by AIMIGo system vs standard hospital-based 12-lead ECG for arrhythmias detection among patients (n=198) with multiple cardiac conditions across the US
- The program aims to establish the equivalence of ECG waveforms b/w AIMIGo synthesized 12-lead ECG & standard 12-lead ECG through ECG parameters analysis incl. amplitudes & intervals. It will also evaluate physician diagnosis accuracy for different arrhythmias using the system
Ref: HeartBeam | Image: HeartBeam
Related News:- Medtronic’s Affera Mapping and Ablation System Receives CE Mark for the Treatment of Atrial Arrhythmias
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
